Evaluation of Aficamten in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: REDWOOD HCM Cohort 4

Long-Term Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)

Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

ENCALS Predictive Survival Model in FORTITUDE-ALS

Sex Differences in Heart Failure with Reduced Ejection Fraction in the GALACTIC-HF Trial

Improvement in KCCQ Scores in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in the REDWOOD HCM OLE Study

Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results from the Randomized Evaluation of Dosing with CK-3773274 in Hypertrophic Cardiomyopathy (REDWOOD-HCM) Open-Label Extension Study